Dermavnt Labs
Manufacturing · Florida, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
398 E Dania Beach Blvd 400, Dania, Flori...Phone Number
(800) 511-4356Website
www.dermavantlabs.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Dermavnt Labs
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company's robust medical dermatology pipeline includes both late-stage and earlier-stage-development product candidates the company believes could address important immuno-dermatological conditions, including psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne.Explore more
Popular SearchesDermavnt Labs IncDermav?nt Labs IncDermavant LabsSIC Code 28,283NAICS Code 32,325Show moreDermavnt Labs Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dermavnt Labs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Dermavnt Labs, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Dermavnt Labs has new funding data
Check out if Dermavnt Labs is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Dermavnt Labs launches new products
Click to see if Dermavnt Labs had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Dermavnt Labs
Earning: See what the market has to say on Dermavnt Labs recently announced quarterly report
Check if Dermavnt Labs has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Dermavnt Labs
Find 2 more new buyers
Compare Similar Companies to Dermavnt Labs
Compare insights from companies similar to Dermavnt Labs, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dermavnt Labs is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dermavnt Labs is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dermavnt Labs.
Dermavnt Labs financials insights
Gather financial insights about Dermavnt Labs, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$200M
Dermavnt Labs Tech Stack
A closer look at the technologies used by Dermavnt Labs
Most Recent Scoops
Event
Events
Event
Events
Award
Award, Employee Relations, Office Operations
New Hire
Dermavnt Labs has announced that Keith Sieradzki has joined the organization as Associate Director, Sales Systems. Previously, Sieradzki served as IT Associate Director, Commercial at Otsuka America Pharmaceutical US.
New Hire
Executive Move
Dermavnt Labs News & Media
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Publishes ADORING 1 & 2 Pivotal Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children with Atopic Dermatitis in JAADDermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Announces FDA Acceptance of sNDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and ChildrenDermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Presents New Data on Patients with Skin of Color from ADORING 1 and 2 Trials of VTAMA® Cream, 1% in Atopic Dermatitis at AAD 2024Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant to Present New ADORING Data at the 2024 American Academy of Dermatology Annual Meeting
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dermavnt Labs
Sign Up For FreeTo access detailed company insights
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical... Read More
